Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

Literature DB >> 19005625

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

H Wiendl, K V Toyka, P Rieckmann, R Gold, H-P Hartung, R Hohlfeld.

Abstract

This review updates and extends earlier Consensus Reports related to current basic and escalating immunomodulatory treatments in multiple sclerosis (MS). The recent literature has been extracted for new evidence from randomized controlled trials, open treatment studies and reported expert opinion, both in original articles and reviews, and evaluates indications and safety issues based on published data. After data extraction from published full length publications and critically weighing the evidence and potential impact of the data, the review has been drafted and circulated within the National MS Societies and the European MS Platform to reach consensus within a very large group of European experts, combining evidence-based criteria and expert opinion where evidence is still incomplete. The review also outlines a few areas of controversy and delineates the need for future research.

Entities: Disease

Mesh：

Substances：

Year: 2008 PMID： 19005625 DOI： 10.1007/s00415-008-0061-1

Source DB: PubMed Journal: J Neurol ISSN： 0340-5354 Impact factor: 4.849

121 in total

1. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

Authors: Valentina Tomassini; Andrea Paolillo; Pierluigi Russo; Elisabetta Giugni; Luca Prosperini; Claudio Gasperini; Guido Antonelli; Stefano Bastianello; Carlo Pozzilli
Journal: J Neurol Date: 2005-09-14 Impact factor: 4.849

Review 2. Human demyelinating disease and the polyomavirus JCV.

Authors: K Khalili; M K White
Journal: Mult Scler Date: 2006-04 Impact factor: 6.312

3. Melanoma complicating treatment with natalizumab for multiple sclerosis.

Authors: John T Mullen; Timothy K Vartanian; Michael B Atkins
Journal: N Engl J Med Date: 2008-02-07 Impact factor: 91.245

Review 4. Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders.

Authors: Helmar C Lehmann; Hans-Peter Hartung; Gerd R Hetzel; Olaf Stüve; Bernd C Kieseier
Journal: Arch Neurol Date: 2006-07

5. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.

Authors: Jordi Río; Mar Tintoré; Carlos Nos; Nieves Téllez; Ingrid Galán; Xavier Montalban
Journal: J Neurol Date: 2005-03-18 Impact factor: 4.849

6. Intravenous Immunoglobulins in MS.

Authors: M Stangel; R Gold
Journal: Int MS J Date: 2005-04

7. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

Authors: Jason Ramtahal; Anu Jacob; Kumar Das; Mike Boggild
Journal: J Neurol Date: 2006-09-21 Impact factor: 4.849

8. Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study.

Authors: M S Freedman; G S Francis; E A C M Sanders; G P A Rice; P O'Connor; G Comi; P Duquette; L Metz; T J Murray; J-P Bouchard; O Abramsky; J Pelletier; F O'Brien
Journal: Mult Scler Date: 2005-02 Impact factor: 6.312

9. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

Authors: Emmanuelle Le Page; Emmanuelle Leray; Grégory Taurin; Marc Coustans; Jacques Chaperon; Sean P Morrissey; Gilles Edan
Journal: J Neurol Neurosurg Psychiatry Date: 2007-09-10 Impact factor: 10.154

Review 10. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.

Authors: Ludwig Kappos; David Bates; Hans-Peter Hartung; Eva Havrdova; David Miller; Chris H Polman; Mads Ravnborg; Stephen L Hauser; Richard A Rudick; Howard L Weiner; Paul W O'Connor; John King; Ernst Wilhelm Radue; Tarek Yousry; Eugene O Major; David B Clifford
Journal: Lancet Neurol Date: 2007-05 Impact factor: 44.182

80 in total

Review 10. [Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis].

Authors: C Warnke; B C Kieseier; U Zettl; H-P Hartung
Journal: Nervenarzt Date: 2009-04 Impact factor: 1.214

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

1. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

Review 2. Human demyelinating disease and the polyomavirus JCV.

3. Melanoma complicating treatment with natalizumab for multiple sclerosis.

Review 4. Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders.

5. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.

6. Intravenous Immunoglobulins in MS.

7. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

8. Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study.

9. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

Review 10. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.

Review 1. Immune mediated diseases and immune modulation in the neurocritical care unit.

Review 2. Vaccination against infection in patients with multiple sclerosis.

3. [Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia].

4. Escalating immunotherapy of multiple sclerosis.

5. Youth and environmental enrichment generate serum exosomes containing miR-219 that promote CNS myelination.

6. Clinical trials in multiple sclerosis: current and future requirements - potential pitfalls.

Review 7. Infection risk in patients on multiple sclerosis therapeutics.

8. What are exosomes and how can they be used in multiple sclerosis therapy?

Review 9. beta2-integrins in demyelinating disease: not adhering to the paradigm.

Review 10. [Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis].